SG/CALL/NOVO-NORDISK B/450/0.2/21.06.24 | Market Closed - Deutsche Boerse AG 15:48:48 2024-05-31 EDT | ||
| 12.63 EUR | +1.94% |
|
| 1 month | +6.94% | ||
| 3 months | +28.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 12.63 | +1.94% |
| 24-05-30 | 12.39 | -0.32% |
| 24-05-29 | 12.43 | +0.24% |
| 24-05-28 | 12.4 | -1.59% |
| 24-05-27 | 12.6 | -2.02% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 03:48 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SV9TA9 |
| ISIN | DE000SV9TA92 |
| Date issued | 2023-07-18 |
| Strike | 450 kr |
| Maturity | 2024-06-21 (20 Days) |
| Parity | 5 : 1 |
| Emission price | 3.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.21 € |
|---|---|
| Lowest since issue | 2.99 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
